Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

678

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: BI 201335
DRUG: Pegylated Interferon-alpha (IFN)
DRUG: Ribavirin (RBV)
DRUG: Placebo

Sponsor

Boehringer Ingelheim